Tue, Jan. 27, 9:10 AM
Tue, Jan. 13, 8:08 AM
- Due to a delay in the production of CT scanners, Philips (NYSE:PHG) is warning that its full-year earnings will take a €225M ($340M) hit.
- The company has resumed shipping its Brilliance iCT product, following an external certification of its quality management system, but the process took longer than expected.
- Q4 EBITA is now estimated at €255M, reflecting legal charges, forex impacts and "softness in certain markets."
- PHG -2.1% premarket
Nov. 12, 2014, 3:53 PM
- Philips (PHG +0.4%) has "attracted bids from several private equity groups for the majority of its lighting components business," Reuters reports. Bain, KKR, and other firms are said to have made offers in the €2.5B-€3B ($3.1B-$3.7B) range.
- The report comes two months after Philips announced it's spinning off its lighting unit. Prior to that, the company combined its Lumileds (LED) and car lights businesses, and has reportedly hired Morgan Stanley to find a buyer for them.
- Cree (CREE +3%), which has often been the subject of M&A rumors (some of them involving Philips) over the years, has rallied today.
Oct. 20, 2014, 4:50 AM
- Philips (NYSE:PHG) reports a net loss of €104M for the quarter ending Sept. 30, compared with a €282M net profit in the same period in 2013.
- The Dutch technology company missed analyst estimates due to several factors, including unfavorable exchange rates, sluggish demand in Europe and China, and the continued fallout from sanctions against Russia.
- Philips' results were also hit by a $467M charge after losing a legal battle to Masimo, which accused Philips of infringing on tech patents.
- PHG -3.5% premarket
Oct. 1, 2014, 6:33 PM
- A Delaware jury has ruled Philips (PHG -2.2%) should pay Masimo (MASI +12.9%) $466M for infringing patents related to fingertip devices that measure blood oxygen and pulse rates. It also cleared Masimo of infringing a Philips patent.
- Philips will almost certainly appeal the ruling, which has led Masimo shares to soar.
- Masimo originally sued Philips in 2009. Philips has been arguing Masimo's patents are invalid due to the obviousness of the technology, and because the patent filings were poorly written.
Jul. 21, 2014, 5:05 AM
- Philips (NYSE:PHG) reports that Q2 net profit fell 23% due to unfavorable exchange rates and the suspension of its health care plant in Cleveland, but countered that earnings should increase in the second half of the year compared with the same period last year. Net profit fell to €242M vs. €317 a year earlier.
- Sales fell 6% Y/Y to €5.29B. Sales were flat on an annual basis, with 7% growth at Philips's consumer electronics business, 1% sales growth in the lighting business and a 3% drop in sales at its health-care business.
- EBITA dropped to €415M, down from €601M Y/Y.
- PHG -0.9% premarket
Jul. 17, 2014, 7:54 AM
- Zacks has downgraded Philips (NYSE:PHG) to a Strong Sell following concerns of weak results at its healthcare division and lower EBITA.
- The company reported weak 2014 results and has been searching a way to restructure its healthcare division to boost financial performance.
- Last quarter Philips' adjusted EBITA also declined to 7.3% of sales from 8% Y/Y.
- PHG -0.9% premarket
Jun. 30, 2014, 12:35 PM
- Both Philips (PHG +4%) and Cree (CREE +3.4%) are up strongly after Philips announced it's merging its Lumileds LED component unit with its automotive lighting business to create a standalone company, and will "explore strategic options to attract capital from third-party investors for [the] business."
- The move could be fueling hopes Philips will try to merge the unit with Cree, which competes against Lumileds in an LED component market that has seen intense price competition. As it is, Cree has often been the subject of M&A rumors (some of them involving Philips).
- Philips, for its part, argues spinning off Lumileds and automotive lighting will help them grow sales to customers who currently view Philips as a rival. The company adds its internal lighting business will be focused on system/lamp sales going forward, and that it's open to an IPO for the spinoff.
Apr. 22, 2014, 9:14 AM
Oct. 21, 2013, 9:15 AM
Apr. 22, 2013, 11:27 AM"The decline of the order intake was very disappointing," says analyst Jos Versteeg referring to weakness in Philips' (PHG) healthcare unit which the company says should still experience 3-4% growth for the full year (Q1 results). When asked on the call how confident the company is about delivering on that prediction, CEO Frans van Houten says "more traction in Northern Europe" and "increased orders on the government side" in the U.S. make him absolutely confident in the healthcare unit's "resiliency" in the eurozone and positioning in the U.S. once "the dust settles" on healthcare reform. (transcript) | Comment!
Apr. 22, 2013, 5:47 AMPhilips (PHG): Q1 net profit -11.5% to €161M, missing consensus of €153M; sales -1% to €5.26B and vs €5.41B, with the drop due to negative currency effects and portfolio changes. Healthcare comparable sales -1% as orders for Healthcare in North America slump by double digits, hurt by U.S. healthcare reforms making hospital CEOs more cautious. Philips reiterates that it expects a slow H1. Shares -3.1% in Amsterdam. (PR) | Comment!
Dec. 17, 2012, 5:36 PM
Oct. 22, 2012, 9:10 AM
Sep. 25, 2012, 2:08 PMNexxus Lighting (NEXS +14.6%) says it's settled pending patent litigation brought against it by Royal Philips Electronics (PHG +0.6%). Philips will grant NEXS an ongoing, royalty-bearing license to its comprehensive portfolio of patented LED technologies under Philips' LED luminaire and retrofit bulb licensing program. NEXS will pay Philips a one-time, lump-sum royalty fee to settle past sales. | Comment!
Jul. 23, 2012, 6:36 AMMore on Philips (PHG) Q2: swings to net profit of €167M from loss of €1.35B a year earlier, which included €1.4B in write-downs. Sales improved at all Philips units, especially in the U.S. and emerging markets, as cost-cutting efforts have an impact. On track to meet 2013 targets of 4%-6% sales growth and EBITA margin of 10%-12% vs. 7.6% in Q2. Confident about China despite slowdown. Shares +6.3% premarket. | Comment!
PHG vs. ETF Alternatives
Other News & PR